BeStock  

Neurocrine Biosciences NBIX

US equityMarket cap rank #1096Drug Manufacturers - Specialty & Generic
$150.57 −$6.02 (-3.84%)
Market closed · Nov 20, 8:20 pm ET · Last extended-hours $150.57 0.00%
Open$156.27
Prev close$156.59
Day range$150.24 – $158.26
Volume1.59M
Market cap$15.24B
P/E (TTM)22.3
Dividend yield–

Valuation

Multiples measured against the stock's own five-year history

Price / earnings22.3x
CheapRich

Near the bottom of its 5-year range · 8th percentile, 5-year average 98.5x

#1861 of 2996 stocks by PE (1 = cheapest)

Price / book3.9x
CheapRich

Near the bottom of its 5-year range · 3rd percentile, 5-year average 5.5x

#4222 of 5338 stocks by PB (1 = cheapest)

Price / sales4.1x
CheapRich

Near the bottom of its 5-year range · 1st percentile, 5-year average 6.2x

#3816 of 5161 stocks by PS (1 = cheapest)

P/E over five years

-148x219x586x953xOct '21Apr '24Nov '26

Dashed line is the 5-year average; the shaded band is one standard deviation either side.

Morningstar fair value estimate

Fair value$165.22
Price vs. fair value-8.9%Trading below the estimate
Star rating★★★☆☆
Economic moatNarrow
UncertaintyMedium
MultipleCurrentForward5y averagePercentile vs. own historyIndustry rank
PB 3.93 – 5.49 3% (cheaper than usual) #4222 of 5338 (1 = cheapest)
PE 22.34 15.56 98.52 8% (cheaper than usual) #1861 of 2996 (1 = cheapest)
PS 4.12 3.39 6.25 1% (cheaper than usual) #3816 of 5161 (1 = cheapest)

Percentile is against this stock’s own 5-year valuation range: higher means it’s trading rich relative to its own history, lower means cheap relative to its own history — it is not a comparison against other companies. Forward multiples use consensus estimates for the next twelve months; a forward multiple below the current one usually signals analysts expect earnings to grow.

Discussion

No comments yet — be the first to weigh in on NBIX.

Sign in to join the discussion.

Scroll to Top